托法替布成功治疗与类脂质渐进性坏死性血管病相关的难治性溃疡 - Suppr

Refractory ulcerations associated with livedoid vasculopathy successfully treated with tofacitinib.

作者信息

Jia Ertao, Yan Guangyao, Xiao Min, Geng Hongling, Wei Jiaxin, Zhang Jianyong

机构信息

The Department of Rheumatology, the fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, China.

The Department of Gynecology, Guangdong Provincial Hospital of Chinese Medicine, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Shenzhen, China.

出版信息

Dermatol Ther. 2020 Nov;33(6):e14470. doi: 10.1111/dth.14470. Epub 2020 Nov 16.

DOI:10.1111/dth.14470

PMID:33112475

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7816240/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84d4/7816240/d6bdb360d82f/DTH-33-e14470-g001.jpg

相似文献

Refractory ulcerations associated with livedoid vasculopathy successfully treated with tofacitinib.

Dermatol Ther. 2020 Nov;33(6):e14470. doi: 10.1111/dth.14470. Epub 2020 Nov 16.

Tofacitinib relieves symptoms of stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173.

J Allergy Clin Immunol. 2017 Apr;139(4):1396-1399.e12. doi: 10.1016/j.jaci.2016.10.030. Epub 2016 Dec 29.

Herpes zoster as a cause of atypical chronic ulcerations associated with tofacitinib.

Dermatol Online J. 2018 Jan 15;24(1):13030/qt3v77g2zg.

Efficacy of new low-dose oral anticoagulants in recalcitrant livedoid vasculopathy.

BMJ Case Rep. 2017 Jul 24;2017:bcr-2017-219943. doi: 10.1136/bcr-2017-219943.

A case of Takayasu arteritis complicated by refractory ulcerative colitis successfully treated with tofacitinib.

Rheumatology (Oxford). 2020 Jul 1;59(7):1773-1775. doi: 10.1093/rheumatology/kez580.

Livedoid vasculopathy - current aspects of diagnosis and treatment of cutaneous infarction.

J Dtsch Dermatol Ges. 2013 May;11(5):407-10. doi: 10.1111/ddg.12064. Epub 2013 Feb 26.

[Vasculitis and vasculopathy].

Acta Med Croatica. 2012 Oct;66 Suppl 1:19-24.

Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction.

Arthritis Rheumatol. 2017 Jan;69(1):148-160. doi: 10.1002/art.39818.

Dabigatran in the management of livedoid vasculopathy.

Clin Exp Dermatol. 2017 Mar;42(2):237-239. doi: 10.1111/ced.13022. Epub 2017 Jan 4.

Ulcerations caused by livedoid vasculopathy associated with a prothrombotic state: Response to warfarin.

J Am Acad Dermatol. 2008 Mar;58(3):512-5. doi: 10.1016/j.jaad.2006.04.087.

引用本文的文献

Refractory Segmental Hyaline Vasculitis Treated with Janus Kinase Inhibitor Tofacitinib: A Case Report.

Clin Cosmet Investig Dermatol. 2025 Jun 12;18:1453-1457. doi: 10.2147/CCID.S530188. eCollection 2025.

Effective Treatment of Livedoid Vasculopathy With Oral Tofacitinib.

Clin Case Rep. 2025 May 28;13(6):e70536. doi: 10.1002/ccr3.70536. eCollection 2025 Jun.

A case report and literature review of livedoid vasculopathy in children.

Front Pediatr. 2025 May 14;13:1537133. doi: 10.3389/fped.2025.1537133. eCollection 2025.

Livedoid vasculopathy, calciphylaxis, and Martorell's hypertensive ulcer: update on ischemic ulcers due to impaired microcirculation of the lower limbs.

An Bras Dermatol. 2025 Mar-Apr;100(2):215-227. doi: 10.1016/j.abd.2024.09.004. Epub 2025 Jan 22.

Pain Management Options in a Patient with Livedoid Vasculopathy and Peripheral Neuropathy.

Eur J Case Rep Intern Med. 2023 Jan 30;10(1):003727. doi: 10.12890/2023_003727. eCollection 2023.

Baricitinib is potentially effective in the treatment of refractory livedoid vasculopathy.

Front Immunol. 2022 Oct 27;13:1008392. doi: 10.3389/fimmu.2022.1008392. eCollection 2022.

Livedoid vasculopathy: A review with focus on terminology and pathogenesis.

Vasc Med. 2022 Dec;27(6):593-603. doi: 10.1177/1358863X221130380. Epub 2022 Oct 26.

Livedoid vasculopathy - A diagnostic and therapeutic challenge.

Front Med (Lausanne). 2022 Oct 3;9:1012178. doi: 10.3389/fmed.2022.1012178. eCollection 2022.

Adalimumab in Treating Refractory Livedoid Vasculopathy.

Vaccines (Basel). 2022 Apr 1;10(4):549. doi: 10.3390/vaccines10040549.

本文引用的文献

Targeting JAK/STAT pathway in Takayasu's arteritis.

Ann Rheum Dis. 2020 Jul;79(7):951-959. doi: 10.1136/annrheumdis-2019-216900. Epub 2020 Mar 25.

Efficacy of an anti-TNF-alpha agent in refractory livedoid vasculopathy: a retrospective analysis.

J Dermatolog Treat. 2022 Feb;33(1):178-183. doi: 10.1080/09546634.2020.1737634. Epub 2020 Mar 9.

Livedoid vasculopathy presenting with leg ulcers.

Rheumatology (Oxford). 2019 Nov 1;58(11):2076. doi: 10.1093/rheumatology/kez126.

Livedoid Vasculopathy: A French Observational Study Including Therapeutic Options.

Acta Derm Venereol. 2018 Oct 10;98(9):842-847. doi: 10.2340/00015555-2965.

Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.

Circulation. 2018 May 1;137(18):1934-1948. doi: 10.1161/CIRCULATIONAHA.117.030423. Epub 2017 Dec 18.

Three cases of lymphocytic thrombophilic arteritis presenting with an annular eruption.

Australas J Dermatol. 2018 May;59(2):e127-e132. doi: 10.1111/ajd.12679. Epub 2017 Jul 28.

Livedoid vasculopathy associated with combined prothrombin G20210A and factor V (Leiden) heterozygosity and MTHFR C677T homozygosity.

J Thromb Thrombolysis. 2008 Aug;26(1):31-4. doi: 10.1007/s11239-008-0214-1. Epub 2008 Mar 23.

Series introduction. JAK-STAT signaling in human disease.

J Clin Invest. 2002 May;109(9):1133-7. doi: 10.1172/JCI15644.

Cytokine signaling in 2002: new surprises in the Jak/Stat pathway.

Cell. 2002 Apr;109 Suppl:S121-31. doi: 10.1016/s0092-8674(02)00701-8.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Refractory ulcerations associated with livedoid vasculopathy successfully treated with tofacitinib.

Dermatol Ther. 2020 Nov;33(6):e14470. doi: 10.1111/dth.14470. Epub 2020 Nov 16.

Tofacitinib relieves symptoms of stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173.

J Allergy Clin Immunol. 2017 Apr;139(4):1396-1399.e12. doi: 10.1016/j.jaci.2016.10.030. Epub 2016 Dec 29.

Herpes zoster as a cause of atypical chronic ulcerations associated with tofacitinib.

Dermatol Online J. 2018 Jan 15;24(1):13030/qt3v77g2zg.

Efficacy of new low-dose oral anticoagulants in recalcitrant livedoid vasculopathy.

BMJ Case Rep. 2017 Jul 24;2017:bcr-2017-219943. doi: 10.1136/bcr-2017-219943.

A case of Takayasu arteritis complicated by refractory ulcerative colitis successfully treated with tofacitinib.

Rheumatology (Oxford). 2020 Jul 1;59(7):1773-1775. doi: 10.1093/rheumatology/kez580.

Livedoid vasculopathy - current aspects of diagnosis and treatment of cutaneous infarction.

J Dtsch Dermatol Ges. 2013 May;11(5):407-10. doi: 10.1111/ddg.12064. Epub 2013 Feb 26.

[Vasculitis and vasculopathy].

Acta Med Croatica. 2012 Oct;66 Suppl 1:19-24.

Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction.

Arthritis Rheumatol. 2017 Jan;69(1):148-160. doi: 10.1002/art.39818.

Dabigatran in the management of livedoid vasculopathy.

Clin Exp Dermatol. 2017 Mar;42(2):237-239. doi: 10.1111/ced.13022. Epub 2017 Jan 4.

Ulcerations caused by livedoid vasculopathy associated with a prothrombotic state: Response to warfarin.

J Am Acad Dermatol. 2008 Mar;58(3):512-5. doi: 10.1016/j.jaad.2006.04.087.

引用本文的文献

Refractory Segmental Hyaline Vasculitis Treated with Janus Kinase Inhibitor Tofacitinib: A Case Report.

Clin Cosmet Investig Dermatol. 2025 Jun 12;18:1453-1457. doi: 10.2147/CCID.S530188. eCollection 2025.

Effective Treatment of Livedoid Vasculopathy With Oral Tofacitinib.

Clin Case Rep. 2025 May 28;13(6):e70536. doi: 10.1002/ccr3.70536. eCollection 2025 Jun.

A case report and literature review of livedoid vasculopathy in children.

Front Pediatr. 2025 May 14;13:1537133. doi: 10.3389/fped.2025.1537133. eCollection 2025.

Livedoid vasculopathy, calciphylaxis, and Martorell's hypertensive ulcer: update on ischemic ulcers due to impaired microcirculation of the lower limbs.

An Bras Dermatol. 2025 Mar-Apr;100(2):215-227. doi: 10.1016/j.abd.2024.09.004. Epub 2025 Jan 22.

Pain Management Options in a Patient with Livedoid Vasculopathy and Peripheral Neuropathy.

Eur J Case Rep Intern Med. 2023 Jan 30;10(1):003727. doi: 10.12890/2023_003727. eCollection 2023.

Baricitinib is potentially effective in the treatment of refractory livedoid vasculopathy.

Front Immunol. 2022 Oct 27;13:1008392. doi: 10.3389/fimmu.2022.1008392. eCollection 2022.

Livedoid vasculopathy: A review with focus on terminology and pathogenesis.

Vasc Med. 2022 Dec;27(6):593-603. doi: 10.1177/1358863X221130380. Epub 2022 Oct 26.

Livedoid vasculopathy - A diagnostic and therapeutic challenge.

Front Med (Lausanne). 2022 Oct 3;9:1012178. doi: 10.3389/fmed.2022.1012178. eCollection 2022.

Adalimumab in Treating Refractory Livedoid Vasculopathy.

Vaccines (Basel). 2022 Apr 1;10(4):549. doi: 10.3390/vaccines10040549.

本文引用的文献

Targeting JAK/STAT pathway in Takayasu's arteritis.

Ann Rheum Dis. 2020 Jul;79(7):951-959. doi: 10.1136/annrheumdis-2019-216900. Epub 2020 Mar 25.

Efficacy of an anti-TNF-alpha agent in refractory livedoid vasculopathy: a retrospective analysis.

J Dermatolog Treat. 2022 Feb;33(1):178-183. doi: 10.1080/09546634.2020.1737634. Epub 2020 Mar 9.

Livedoid vasculopathy presenting with leg ulcers.

Rheumatology (Oxford). 2019 Nov 1;58(11):2076. doi: 10.1093/rheumatology/kez126.

Livedoid Vasculopathy: A French Observational Study Including Therapeutic Options.

Acta Derm Venereol. 2018 Oct 10;98(9):842-847. doi: 10.2340/00015555-2965.

Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.

Circulation. 2018 May 1;137(18):1934-1948. doi: 10.1161/CIRCULATIONAHA.117.030423. Epub 2017 Dec 18.

Three cases of lymphocytic thrombophilic arteritis presenting with an annular eruption.

Australas J Dermatol. 2018 May;59(2):e127-e132. doi: 10.1111/ajd.12679. Epub 2017 Jul 28.

Livedoid vasculopathy associated with combined prothrombin G20210A and factor V (Leiden) heterozygosity and MTHFR C677T homozygosity.

J Thromb Thrombolysis. 2008 Aug;26(1):31-4. doi: 10.1007/s11239-008-0214-1. Epub 2008 Mar 23.

Series introduction. JAK-STAT signaling in human disease.

J Clin Invest. 2002 May;109(9):1133-7. doi: 10.1172/JCI15644.

Cytokine signaling in 2002: new surprises in the Jak/Stat pathway.

Cell. 2002 Apr;109 Suppl:S121-31. doi: 10.1016/s0092-8674(02)00701-8.

Refractory ulcerations associated with livedoid vasculopathy successfully treated with tofacitinib.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献